Ariadni Mavrou

List of Publications by Year in descending order

39 papers	992 citations	430874 18 h-index	434195 31 g-index
40 all docs	40 docs citations	40 times ranked	1288 citing authors

#	Article	IF	Citations
1	Dysregulated placental microRNAs in Early and Late onset Preeclampsia. Placenta, 2018, 61, 24-32.	1.5	49
2	Plasma biomarkers for the identification of women at risk for early-onset preeclampsia. Expert Review of Proteomics, 2017, 14, 269-276.	3.0	42
3	Urine proteomic studies in preeclampsia. Proteomics - Clinical Applications, 2015, 9, 501-506.	1.6	16
4	Validation of Serum Biomarkers Derived from Proteomic Analysis for the Early Screening of Preeclampsia. Disease Markers, 2015, 2015, 1-7.	1.3	11
5	miRNAs in pregnancy-related complications. Expert Review of Molecular Diagnostics, 2015, 15, 999-1010.	3.1	41
6	Screening of UBE3A gene in patients referred for Angelman Syndrome. European Journal of Paediatric Neurology, 2013, 17, 366-373.	1.6	6
7	Screening Human Genes for Small Alterations Performing an Enzymatic Cleavage Mismatched Analysis (ECMA) Protocol. Molecular Biotechnology, 2013, 55, 1-9.	2.4	8
8	RASSF1A in maternal plasma as a molecular marker of preeclampsia. Prenatal Diagnosis, 2013, 33, 682-687.	2.3	42
9	Early non-invasive detection of fetal Y chromosome sequences in maternal plasma using multiplex PCR. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2012, 161, 34-37.	1.1	28
10	Proteomic analysis of amniotic fluid for the diagnosis of fetal aneuploidies. Expert Review of Proteomics, 2011, 8, 175-185.	3.0	14
11	Application of proteomics for the identification of biomarkers in amniotic fluid: are we ready to provide a reliable prediction?. EPMA Journal, 2011, 2, 149-155.	6.1	11
12	Biomarker development for non-invasive prenatal diagnosis of fetal aneuploidies: predictive reliability and potential clinical application. EPMA Journal, 2011, 2, 157-161.	6.1	0
13	Non-invasive prenatal diagnosis using cell-free fetal nucleic acids in maternal plasma: Progress overview beyond predictive and personalized diagnosis. EPMA Journal, 2011, 2, 163-171.	6.1	19
14	A multiplex PCR for non-invasive fetal RHD genotyping using cell-free fetal DNA. In Vivo, 2011, 25, 411-7.	1.3	12
15	Proteomic analysis of amniotic fluid in pregnancies with Klinefelter syndrome foetuses. Journal of Proteomics, 2010, 73, 943-950.	2.4	34
16	Potential Biomarkers for Turner in Maternal Plasma: Possibility for Noninvasive Prenatal Diagnosis. Journal of Proteome Research, 2010, 9, 5164-5170.	3.7	23
17	Noninvasive fetal RhD genotyping from maternal blood. Expert Review of Molecular Diagnostics, 2010, 10, 285-296.	3.1	13
18	Application of proteomics for diagnosis of fetal aneuploidies and pregnancy complications. Journal of Proteomics, 2009, 72, 731-739.	2.4	13

#	Article	IF	Citations
19	Proteomics in prenatal diagnosis. Expert Review of Proteomics, 2009, 6, 111-113.	3.0	9
20	Application of proteomics for the identification of differentially expressed protein markers for Down syndrome in maternal plasma. Prenatal Diagnosis, 2008, 28, 691-698.	2.3	60
21	Mass spectrometryâ€based proteomics in reproductive medicine. Mass Spectrometry Reviews, 2008, 27, 624-634.	5.4	53
22	Proteomic Analysis of Amniotic Fluid in Pregnancies with Turner Syndrome Fetuses. Journal of Proteome Research, 2008, 7, 1862-1866.	3.7	33
23	Proteomic analysis of human reproductive fluids. Proteomics - Clinical Applications, 2007, 1, 853-860.	1.6	8
24	Screening Human Genes for Small Alterations Performing an Enzymatic Cleavage Mismatched Analysis (ECMA) Protocol. Molecular Biotechnology, 2007, 37, 212-219.	2.4	10
25	Proteomic analysis of amniotic fluid in pregnancies with Down syndrome. Proteomics, 2006, 6, 4410-4419.	2.2	94
26	Detection of Fetal NRBCs in Maternal Blood of Pregnant Carriers of Î²-Thalassemia Using Anti-Î³ and Anti-Îµ Monoclonal Antibodies. Annals of the New York Academy of Sciences, 2006, 945, 151-152.	3.8	4
27	The normal human amniotic fluid supernatant proteome. In Vivo, 2006, 20, 479-90.	1.3	47
28	Clinical Manifestations and Molecular Investigation of 50 Patients with Williams Syndrome in the Greek Population. Pediatric Research, 2005, 57, 789-795.	2.3	47
29	Non-Hodgkin lymphoma in a child with Williams syndrome. Cancer Genetics and Cytogenetics, 2004, 154, 86-88.	1.0	21
30	Evaluation at single cell level of residual Philadelphia negative hemopoietic stem cells in chronic phase CML patients. Cancer Genetics and Cytogenetics, 2000, 122, 93-100.	1.0	5
31	Screening for minor changes in the distal part of the human dystrophin gene in Greek DMD/BMD patients. European Journal of Human Genetics, 1999, 7, 179-187.	2.8	8
32	Improved Specificity of NRBC Detection in Chorionic Villus Sample Supernatant Fluids Using Anti-Zeta and Anti-Epsilon Monoclonal Antibodies. Fetal Diagnosis and Therapy, 1999, 14, 291-295.	1.4	18
33	Population screening in Greece for prevention of genetic diseases. , 1999, , 89-93.		0
34	Awareness and use of prenatal diagnosis among Greek women: a national survey. Prenatal Diagnosis, 1998, 18, 349-355.	2.3	15
35	The Growth Pattern and Final Height of Girls With Turner Syndrome With and Without Human Growth Hormone Treatment. Pediatrics, 1998, 101, 663-668.	2.1	29
36	Prenatal Diagnosis Services in Greece. European Journal of Human Genetics, 1997, 5, 39-41.	2.8	3

#	Article	IF	Citations
37	Mapping dystrophin gene recombinants in Greek DMD/BMD families: low recombination frequencies in the STR region. Human Genetics, 1995, 96, 423-6.	3.8	5
38	Autosomal folate sensitive fragile sites in normal and mentally retarded individuals in Greece. American Journal of Medical Genetics Part A, 1991, 38, 437-439.	2.4	8
39	Martin-Bell syndrome in Greece, with report of another 47,XXY fragile X patient. American Journal of Medical Genetics Part A, 1988, 31, 735-739.	2.4	21